Background Multigene panels can be a cost-and time-effective alternative to sequentially
testing multiple genes, especially with a mixed family cancer phenotype. However, moving …

Historically, genetic testing (and billing) for hereditary cancer risk was essentially performed
gene by gene, with clinicians ordering testing only for the genes most likely to explain a …

Background Clinical interpretation of genetic test results is complicated by variants of
uncertain significance (VUS) that have an unknown impact on health but can be clarified …

Purpose: Screening multiple genes for inherited cancer predisposition expands
opportunities for cancer prevention; however, reports of variants of uncertain significance …

This study aims to assess multi-gene panel testing in an ethnically diverse clinical cancer
genetics practice. We conducted a retrospective study of individuals with a personal or …

Multi‐gene cancer panels often identify variants of uncertain clinical significance (VUS) that
pose a challenge to health care providers in managing a patient's cancer risk. Family …

Cancer genetics professionals face a new opportunity and challenge in adapting to the
availability of cancer genetic testing panels, now available as a result of Next Generation …

The advent of massively parallel (next-generation) sequencing presents a tremendous
opportunity for clinical cancer genetics. The ability to affordably sequence many (or even all) …

Purpose Genetic testing of individuals often results in identification of genomic variants of
unknown significance (VUS). Multiple lines of evidence are used to help determine the …

Purpose Massively parallel sequencing allows simultaneous testing of multiple genes
associated with cancer susceptibility. Guidelines are available for variant classification; …